NASDAQ · LSTA

Lisata Therapeutics, Inc.

$1.44 -$0.23 (-13.77%) 1D After hours

Key Metrics

$15.21M
Market cap
64.71×
P/E · TTM
$0
Revenue · TTM
$235.00K
Net income
EPS · TTM $0.03
Dividend yield
Free cash flow −$13.63M
Beta · 1Y 0.01
EBITDA · TTM $886.00K
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Mar 9 high, the share price fell 71%.

    Peak close $5.04 on Mar 9; trough close $1.44 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -71%
  • Jul 24
    The stock moved -21.2% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 24
  • Jul 21
    The stock moved -36.5% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jul 21
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$15.21M
Enterprise value
Shares outstanding9.1M
52-wk range$1.43 – $5.07
Avg volume · 20D43.4K
Net cash
Book value / share$1.27
IndustryPharmaceutical Preparations
ExchangeNASDAQ
About Lisata Therapeutics, Inc.
IPO dateMar 1, 1999
Employees21

Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E64.71
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №$0.88

Profitability

Gross
Operating
Net
FCF
ROE / ROIC 2.2% · -37.1%

Financial Health

Current ratio4.23
Quick ratio
Debt / equity
Debt / EBITDA
Net cash
Working capital$10.71M

Cash Flow · TTM

Operating CF −$13.63M
Capex $0
Free cash flow −$13.63M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

1 / 9
Weak fundamentals · 1 of 9 signals passing

Altman Z-Score

-52.9
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

$0.88 vs $1.44
Trades 1.6× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings